Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02128971
Recruitment Status : Unknown
Verified May 2014 by Albion.
Recruitment status was:  Recruiting
First Posted : May 1, 2014
Last Update Posted : May 6, 2014
Sponsor:
Collaborator:
Sprim Advanced Life Sciences
Information provided by (Responsible Party):
Albion

Brief Summary:
The purpose of this study is to compare the gastrointestinal (GI) tolerability of 5 different iron supplements (Ferrochel®, Sumalate®,ferrous fumarate, ferrous sulfate and ferric glycinate) at the same dose (90mg) and placebo.

Condition or disease Intervention/treatment Phase
Anemia Dietary Supplement: Ferrochel® 90 mg Dietary Supplement: Sumalate® 90 mg Dietary Supplement: Ferrous fumarate 90 mg Dietary Supplement: Ferrous Sulfate 90 mg Dietary Supplement: Ferric Glycinate 90 mg Dietary Supplement: Placebo Phase 2

  Hide Detailed Description

Detailed Description:

Anemia, the most common disorder of blood, is characterized by a decrease in number of red blood cells (RBCs) or less than normal quantity of hemoglobin in blood.Hemoglobin is an oxygen-carrying protein inside RBCs that transports oxygen from the respiratory organs to the rest of body. Several vitamins, minerals and nutrients are required for the development and production of RBCs, such as vitamin B12, folic acid and iron. Iron is an essential component of hemoglobin. Iron deficiency accounts for half of the anemia cases worldwide, and iron deficiency anemia is the most common nutritional disorder in the world.Iron deficiency can be the result of inadequate intake in the diet, poor absorption, the extra needs during growth or pregnancy, and blood loss. Thus, children and women are at highest risk.

Full blood count and hemoglobin measurements are used to diagnose anemia, and measurement of serum ferritin level (cutoff of 12-15 mg/l) is considered as the best single and non-invasive test for the diagnosis of iron-deficiency. Treatment of anemia depends on the cause and the severity. Oral iron supplement is the simplest and most cost-effective option to treat anemia and replenish body storage.

The objective of this clinical trial is to compare the gastrointestinal (GI) tolerability of 5 different iron supplements (Ferrochel®, Sumalate®,ferrous fumarate, ferrous sulfate and ferric glycinate) at the same dose (90mg)and placebo. The primary objective is to compare the gastrointestinal tolerability of the above quoted products through:

  • Self-assessment questionnaires - Gastrointestinal Symptoms Questionnaire5
  • Self reported diaries

The Secondary objective of the study is to assess the change from baseline of the parameters below:

  • Hemoglobin level
  • Hematocrit level
  • Ferritin level

This prospective clinical trial is a single-center, six-arms, randomized, double-blinded, parallel study. Subject will be screened according to inclusion exclusion criteria, and blood sample will be collected to ensure the hemoglobin and ferritin levels. Subject also will be asked to complete the Gastrointestinal Symptoms Questionnaire. The study product will be administered 30 days, orally once daily in the morning after breakfast. The study plan as follow:

Visit 1: Screening / Baseline (day -7)

  1. Protocol information will be given by the investigator to potential subjects. Each participant will sign a consent form that further explains what is entailed by participating in the study as well as providing subjects with information on how to report any adverse events (AEs) that may arise.
  2. Collection of demographic information and medical history.
  3. A 10-mL blood sample will be collected by venipuncture for lab analysis of hemoglobin and ferritin.
  4. Subjects will complete the Gastrointestinal Symptoms Questionnaire for baseline record.
  5. Subjects that meet the inclusion and exclusion criteria will be scheduled for visit 2

Visit 2: Day 0

  1. PI or designee will assign an unique subject ID number to each eligible subject in ascending order; the subject ID corresponds to an assigned investigational product code on the subject list and to the label on the investigational product (IP) given to the subject.
  2. Subjects will complete the Gastrointestinal Symptoms Questionnaire.
  3. A 10-ml blood sample will be collected by venipuncture for lab analysis of hemoglobin, ferritin and hematocrit.
  4. Subject diary will be dispensed.
  5. The PI or designee will dispense the investigational product capsules to subjects, according to the subject list provided. Each subject will receive sufficient investigational product capsules to last for 30 days.
  6. Subjects will begin to consume the investigational product capsule once a day, at the same time after breakfast, for 30 days starting on Day 1.

Visit 3: Day 15 Window period ± 2 days will be allowed for this visit

  1. A 10-ml blood sample will be collected by venipuncture for lab analysis of hemoglobin, ferritin and hematocrit.
  2. Subjects will bring their unused IP to the study site. Compliance will be monitored by counting the remaining investigational product capsules. The remaining IP capsules will then be returned to the subject.
  3. Subjects will complete the Gastrointestinal Symptoms Questionnaire.
  4. Subject's diary will be collected and new diary will be dispensed.

Visit 4: Day 30 Window period ± 2 days will be allowed for this visit

  1. A 10-mlblood sample will be collected by venipuncture for lab analysis of hemoglobin, ferritin and hematocrit.
  2. The PI or designee will collect any remaining investigational product. Compliance will be monitored by counting the remaining investigational product capsules.
  3. Subjects will complete the Gastrointestinal Symptoms Questionnaire.
  4. Subject's diary will be collected.
  5. New Subject diary will be dispensed.

Visit 5: Day 37 Window period ± 2 days will be allowed for this visit

  1. Subjects will complete the Gastrointestinal Symptoms Questionnaire.
  2. Subject diaries will be collected.

Adverse Event and Serious Adverse Event will be recorded since the subjects begin consuming the investigational product and throughout the study. SAE should be recorded in the SAE form and reported to Sponsor or CRA within 24 hours. All SAE will be reported to Ethic Committee and Regulatory Authority.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo
Study Start Date : April 2014
Estimated Primary Completion Date : June 2014
Estimated Study Completion Date : August 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Ferrochel® 90 mg
Ferrochel® capsule 90 mg OD for 30 days
Dietary Supplement: Ferrochel® 90 mg
Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Other Name: Ferrous Bisglycinate

Active Comparator: Sumalate® 90 mg
Sumalate® capsule 90 mg OD for 30 days
Dietary Supplement: Sumalate® 90 mg
Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
Other Name: Ferrous aspartoglycinate

Active Comparator: Ferrous Fumarate 90 mg
Ferrous Fumarate capsule 90 mg OD for 30 days
Dietary Supplement: Ferrous fumarate 90 mg
Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days

Active Comparator: Ferrous Sulfate 90 mg
Ferrous Sulfate capsule 90 mg OD for 30 days
Dietary Supplement: Ferrous Sulfate 90 mg
Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days

Active Comparator: Ferric glycinate 90 mg
Ferric glycinate capsule 90 mg OD for 30 days
Dietary Supplement: Ferric Glycinate 90 mg
Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days

Active Comparator: Placebo
Placebo capsule OD for 30 days
Dietary Supplement: Placebo
Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days




Primary Outcome Measures :
  1. Gastrointestinal questionnaire to measure the gastrointestinal tolerability [ Time Frame: change from baseline in Gastrointestinal questionnaire on 7 days after the last dose of 30 days investigational product consumption ]
    The gastrointestinal tolerability of the products will be assessed by self-assessment questionnaires and self-reported diaries at baseline (screening), day 0, day 15, day 30 of investigational product consumption, and 7 days after finished the investigational product.


Secondary Outcome Measures :
  1. the laboratory result to measure the change from baseline [ Time Frame: up to 30 days of investigational product consumption ]
    hemoglobin levels of each subject will be measured at baseline (screening), day 0, day 15 and day 30 of investigational product consumption

  2. the laboratory result to measure the change from baseline [ Time Frame: up to 30 days of investigational product consumption ]
    Hematocrit levels of each subject will be measured at baseline (screening), day 0, day 15 and day 30 of investigational product consumption

  3. the laboratory result to measure the change from baseline [ Time Frame: up to 30 days of investigational product consumption ]
    Ferritin levels of each subject will be measured at baseline (screening), day 0, day 15 and day 30 of investigational product consumption



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women, 18-50 years of age, inclusive
  2. Hemoglobin 8 g/dl - 11 g/dl
  3. Ferritin levels < 20 mcg/l (20 ng/mL)
  4. Subject, or subject's acceptable representative, has voluntarily signed and dated an informed consent form, approved by a local Ethics Committee/Institutional Review Board prior to any participation in the study

Exclusion Criteria:

  1. Pregnant or lactating
  2. Amenorrhea
  3. Severe anemia (hemoglobin 7 g/dl) or other blood abnormality (e.g., leukopenia, thrombocytopenia, polycythemia vera)
  4. Serious illness that may confound study results or interfere with compliance
  5. Subjects that have followed specific diet, eg. high protein diet, within 30 days prior to study start
  6. Subjects that have taken iron supplements within 30 days prior to study start
  7. Subjects that are allergic to any of the ingredients in the products
  8. Participation in other clinical trials within three months prior to screening
  9. Known intolerance to oral iron supplements
  10. Habitual smokers (more than 3 cigarettes per week)
  11. Other medical conditions that, in the investigator's opinion, may confound study results or prelude the subject's ability to safely complete the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02128971


Contacts
Layout table for location contacts
Contact: Eka Windari Rusman +62 21 83701201 eka.windari@sprim.com
Contact: Jennifer Hartle 8017734631 jhartle@albionminerals.com

Locations
Layout table for location information
Indonesia
Laboratory Faculty of Pharmacy, Universitas Indonesia Recruiting
Depok, West Java, Indonesia, 16424
Contact: Yahdiana Harahap, Professor    +62-21-7270031    yahdiana.ms@ui.ac.id   
Sponsors and Collaborators
Albion
Sprim Advanced Life Sciences
Investigators
Layout table for investigator information
Principal Investigator: Yahdiana Harahap, Professor Laboratory Faculty of Pharmacy, Universitas Indonesia

Layout table for additonal information
Responsible Party: Albion
ClinicalTrials.gov Identifier: NCT02128971     History of Changes
Other Study ID Numbers: AM-FEB-INDO-2013-01
First Posted: May 1, 2014    Key Record Dates
Last Update Posted: May 6, 2014
Last Verified: May 2014
Keywords provided by Albion:
Iron supplement study
Additional relevant MeSH terms:
Layout table for MeSH terms
Ferrous fumarate
Glycine
Trace Elements
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action